Success Metrics

Clinical Success Rate
92.7%

Based on 268 completed trials

Completion Rate
93%(268/289)
Active Trials
23(7%)
Results Posted
60%(161 trials)
Terminated
21(6%)

Phase Distribution

Ph phase_4
9
3%
Ph phase_2
146
42%
Ph phase_1
54
16%
Ph early_phase_1
1
0%
Ph phase_3
120
35%
Ph not_applicable
14
4%

Phase Distribution

55

Early Stage

146

Mid Stage

129

Late Stage

Phase Distribution344 total trials
Early Phase 1First-in-human
1(0.3%)
Phase 1Safety & dosage
54(15.7%)
Phase 2Efficacy & side effects
146(42.4%)
Phase 3Large-scale testing
120(34.9%)
Phase 4Post-market surveillance
9(2.6%)
N/ANon-phased studies
14(4.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.4%

268 of 303 finished

Non-Completion Rate

11.6%

35 ended early

Currently Active

23

trials recruiting

Total Trials

345

all time

Status Distribution
Active(32)
Completed(268)
Terminated(35)
Other(10)

Detailed Status

Completed268
Terminated21
Recruiting16
Withdrawn14
unknown9
Not yet recruiting8

Development Timeline

Analytics

Development Status

Total Trials
345
Active
23
Success Rate
92.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (0.3%)
Phase 154 (15.7%)
Phase 2146 (42.4%)
Phase 3120 (34.9%)
Phase 49 (2.6%)
N/A14 (4.1%)

Trials by Status

completed26878%
not_yet_recruiting82%
suspended10%
active_not_recruiting72%
withdrawn144%
terminated216%
unknown93%
enrolling_by_invitation10%
recruiting165%

Recent Activity

Clinical Trials (345)

Showing 20 of 345 trialsScroll for more
NCT05066997Phase 2

A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)

Completed
NCT07531043Phase 3

An Evaluation of the Efficacy and Safety of FID 123472 Ophthalmic Solution for the Reduction of Ocular Redness

Not Yet Recruiting
NCT06172257Phase 3

A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)

Completed
NCT05891795Phase 1

Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy

Active Not Recruiting
NCT05586152Phase 1

Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease

Completed
NCT06073132Phase 2

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Active Not Recruiting
NCT07144852Phase 3

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities

Recruiting
NCT07453888Phase 3

Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Not Yet Recruiting
NCT07395232Phase 3

An Efficacy and Safety Study of DFL24498 in the Treatment of AKC

Recruiting
NCT07522242Phase 2

Safety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia Progression

Recruiting
NCT07519902Phase 3

An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED

Not Yet Recruiting
NCT07503886Phase 2

An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

Not Yet Recruiting
NCT03372811Phase 2

Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-IIb Trial)

Completed
NCT05521438Phase 2

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

Active Not Recruiting
NCT07128628Phase 2

A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease

Recruiting
NCT07443202Phase 2

Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)

Enrolling By Invitation
NCT05728944Phase 3

Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia

Completed
NCT06312813Phase 2

Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea

Recruiting
NCT06830863Phase 1

A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity

Recruiting
NCT07377097Not Applicable

Effects of Sweetener Consumption on Risk Factors for Heart Disease in Prediabetic Subjects

Not Yet Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
345